Form 4: TWST COO Sells Shares for Tax Obligations

Twist Bioscience Corporation's President and COO, Patrick John Finn, sold 3,189 shares of common stock to cover tax withholding obligations related to vested Restricted Stock Units.

Summary

• Patrick John Finn, President and COO of Twist Bioscience Corporation (TWST), sold 3,189 shares of common stock.
• The transaction occurred on August 4, 2025, at a price of $28.364 per share.
• The sale was non-discretionary, mandated by the company's equity incentive plans to cover tax withholding obligations associated with the vesting of Restricted Stock Units.
• Following this transaction, Patrick John Finn beneficially owns 235,153 shares of common stock.

Sentiment

Score: 5

Explanation: The sentiment is neutral. The transaction is a non-discretionary 'sell to cover' for tax purposes, which is a routine event for equity compensation and does not reflect a voluntary decision by the insider to sell shares.

Positives

• The sale was non-discretionary, indicating it was not a voluntary decision by the insider to reduce exposure.
• It fulfills tax obligations related to vested equity, a standard practice in compensation plans.

Negatives

• A reduction in direct beneficial ownership by a key executive, even if non-discretionary.

Future Outlook

No forward-looking statements or guidance are provided in this filing, as it pertains solely to an insider transaction.

Industry Context

This Form 4 filing details a routine insider transaction for tax purposes and does not provide information relevant to broader industry trends or competitive analysis.

Comparison to Industry Standards

• This filing is a standard Form 4 for an insider 'sell to cover' transaction, which is a common practice across publicly traded companies to satisfy tax obligations arising from equity compensation. It does not contain information for direct comparison to specific companies, projects, or results.

Stakeholder Impact

• Shareholders: Minimal direct impact as it's a non-discretionary tax-related sale, not indicative of a change in management's confidence.
• Employees: No direct impact mentioned.
• Customers/Suppliers/Creditors: No direct impact mentioned.

Key Dates

Keywords

Twist Bioscience, TWST, Patrick John Finn, insider trading, Form 4, share sale, restricted stock units, RSU, tax withholding, corporate governance